PROGRAM

REGISTRATION FEES

LOCATION & HOTEL INFO

From Data to Discovery: Harnessing the Power of Multi-Omics

 

Dr. Mike Snyder – a leading expert in the field of genomics and personalized medicine – will present a comprehensive overview of the multi-omics landscape. This session will explore the relevance of multi-omics to enhancing our understanding of complex biological systems and diseases, offering insights into how this integrative approach can lead to more precise and predictive healthcare solutions. Dr. Snyder will also discuss the impact of multi-omics on drug development, disease diagnosis, and personalized treatment plans, highlighting practical applications that could benefit executive members and their companies.

 

Dr. Michael Snyder is the Stanford W. Ascherman Professor and Chair of the Genetics Department at Stanford Medicine, leading the Center for Genomics and Personalized Medicine since 2009. Under his leadership, Stanford has been top-ranked in Genetics, Genomics, and Bioinformatics for the past decade. A pioneer in personalized medicine, Dr. Snyder’s work in longitudinal baseline profiling and “omic” technologies has advanced precision medicine. His co-founded companies have raised $242 million in venture capital, exceeding $6 billion in value. He also serves on several corporate boards.

Revolutionizing Disease Understanding with Multi-Omics Research

 

Dr. Gary Patti, a renowned expert in metabolomics and key member of the NIH Multi-Omics for Health and Disease Consortium, will discuss the transformative potential of multi-omics research. This NIH consortium advances the generation and analysis of multi-omics data for human health research. As principal investigator of this consortium, Dr. Patti leads a central production center that functions as a hub for multi-omics analyses for materials from consortium members at each of six disease study sites identified by the NIH. Dr. Patti will share insights into how these efforts are revolutionizing disease understanding, with significant implications for ALDA member companies.

 

Gary J. Patti, PhD, is a leading researcher in the field of metabolomics and the Michael and Tana Powell Professor at Washington University in St. Louis, where he holds appointments in the department of chemistry and the department of medicine. Dr. Patti’s research focuses on developing and applying both mass spectrometry-based and NMR-based metabolomics technologies to enhance our understanding of human health. Dr. Patti is also founder of Panome Bio and has helped advance the field of metabolomics through the development of gold-standard software tools, commercial benchmarking kits, and NIH-led trials.

AI Methods for Linking Multi-Omics Data and Phenotypes

 

Dr. Russ Altman, a distinguished professor at Stanford University and a pioneer in the field of bioinformatics, will discuss how AI technologies are being used for multi-omics integration such as deep neural networks, transformers, and multi-modal data integration—and how they can be used to extract value from this data. This session will take a close look at which tools are likely to be used—as well as expected pros/cons of performance—to analyze the data. He will also explore AI capabilities for individual omics and how they can be used to integrate multi-omics.

 

Professor Russ Altman of Stanford University specializes in bioengineering, genetics, medicine, and computer science, focusing on the application of computing and informatics to medicine. His research explores drug actions at various biological levels and the impact of genetic variation on drug response. Altman has received numerous accolades, including the U.S. Presidential Early Career Award, and serves on the NIH Director’s Advisory Committee. He founded the PharmGKB knowledge base and advises pharmacogenomics companies.

Multi-Omics Integration in Drug Discovery & Development

 

Explore the transformative power of multi-omics in enhancing our understanding of human biology and its implications for health and disease over time. This session will delve into the innovative applications of multi-omics in drug discovery and development, highlighting its growing impact on the ALDA member community. Attendees will gain insights into the practical implications of multi-omics technologies for the industry and their businesses.

 

Jonathan Usuka is a business leader and scientist with over 25 years of experience in the pharmaceutical industry, specializing in business strategy and data science. Before joining Sapient as Chief Business Officer, he held senior roles at REALM IDx, McKinsey & Company, Celgene, and Roche. Dr. Usuka earned his PhD from Stanford University and an MBA from The Wharton School. At Sapient, he drives business strategy, leveraging multi-omics data to advance drug discovery and personalized medicine.

5:30-7 p.m.
Reception: Live Jazz by the Sea

Enjoy jazz by the Brian Andres Trio, drinks, a Half Moon Bay seafood boil, and a variety of appetizers while connecting with fellow attendees on the hotel’s scenic Ocean Lawn. Bring your jacket.